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Objective: This study analyzed device-specific aneurysm sac morphology after endovascular aneurysm repair (EVAR) with
low-permeability devices.
Methods: Between September 2004 and May 2006, 122 patients were treated with EVAR. Three different devices were
implanted: 47 Zenith (Cook, Indianapolis, Ind), 46 AneuRx (Medtronic, Santa Rosa, Calif) with Resilient Dacron Graft
Material, and 29 Excluder (W. L. Gore & Associates, Flagstaff, Ariz) with low-porosity polytetrafluoroethylene (PTFE).
Patients were followed up at 1, 6, and 12 months and then biannually with computed tomography (CT) angiography.
Standard axial two-dimensional CT measurements were obtained and compared with preoperative imaging. The
preoperative scan served as a baseline, and the minor axis diameter, measured at the largest axial cut of the abdominal
aortic aneurysm, was compared with the same measurement at follow-up.
Results: Patient age, sex, and preoperative aneurysm morphology were similar among groups. Patients receiving the Zenith
endograft had a significantly larger neck diameter; however, there was no difference in the neck length between groups. The
rate of type II endoleaks was similar for the Zenith (17%), AneuRx (17%), and Excluder (14%). At 1, 6, 12, and 18 m onths, all three
grafts were associated with sac shrinkage. The resulting decreases in mean aneurysm size at 18 months and corresponding
shrinkage were Zenith, 11%, 6.4  1.8 mm; AneuRx, 18.9%, 12.7  2.7 mm; and the Excluder, 5.5%, 3.3  0.9 (P < .05). The
sac size in the 19 patients with a type II endoleak decreased 8.06% compared with a 15.43% decrease in sac size in patients
without endoleak at 6 months. No significant sac expansion >5 mm has been observed among any of the groups to date.
Conclusions: Sac regression with all devices appears to have been favorably influenced by the new generation of graft
materials and is improved compared with published reports of older generation graft materials for the AneuRx and
Excluder. However, there is a trend toward greater sac regression with devices using Dacron vs PTFE. The relationship
of aneurysm morphology and long-term effects on aortic stent grafts is yet to be determined. ( J Vasc Surg 2008;47:
702-7.)Since the introduction of endovascular aneurysm repair
(EVAR) in 1991, as many as 10 grafts have been designed and
implanted in clinical trials. Current endografts vary in type of
fixation (suprarenal vs infrarenal, presence of hooks/barbs),
graft material (polytetrafluoroethylene [PTFE] vs Dacron),
and delivery system. Device-specific outcomes have been
examined for differences in the rates of endoleak, graft
migration, and changes in sac morphology after EVAR.
Several trials have now suggested that sac regression or
enlargement after EVAR may be device specific. The orig-
inal Excluder (W. L. Gore & Associates, Flagstaff, Ariz) has
been associated with sac enlargement, whereas the AneuRx
(Medtronic, Santa Rosa, Calif) has been associated with a
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702stable aneurysm size after repair. Longer-body stent grafts,
including the Talent (Medtronic) and Zenith (Cook, Indi-
anapolis, Ind), have been associated with increased sac
regression and reduced incidence of type II endoleaks.1-7
Although stable sac size has not been associated with
aneurysm rupture, regression of aneurysm sac size is currently
believed to be a marker for successful repair. Sac regression
remains a reassuring sign of aneurysm exclusion and depres-
surization of the aneurysm sac, the primary goals of EVAR.8
Sac enlargement after EVAR, however, is associated with
continued or intermittent pressurization of the sac, secondary
to endoleak or endotension, and has been associated with late
aneurysm rupture.6,9 Sac enlargement after EVAR, without
evidence of endoleak, has been attributed largely to material
porosity; the manufacturers of the Excluder and AneuRx
devices have modified their graft material since 2004 and now
use fabric with reduced permeability.1,4,10-12 The Zenith en-
dograft, originally designed with a low-permeability Dacron,
has often been used as a basis for comparison for other graft
types because it is associated with the highest reported rates of
sac regression.1-3,5
The purpose of this study was to analyze device-
specific aneurysm sac morphology after EVAR with
low-permeability devices. We monitored morphology
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cluder, Zenith, and AneuRx devices.
METHODS
Study design. From September 2004 to May 2006,
122 consecutive patients underwent EVAR at two institu-
tions in Texas. Three different endoprosthesis were im-
planted: 47 Zenith, 46 AneuRx with Resilient Dacron
Graft Material, and 29 Excluder with low-porosity PTFE.
Patient selection. All patients underwent a preopera-
tive evaluation with computed tomographic angiography
(CTA). Preoperative patient comorbidities captured in-
cluded coronary artery disease, chronic obstructive pulmo-
nary disease, chronic renal insufficiency, peripheral vascular
disease, and cerebrovascular disease, and the overall num-
ber for each patient are summarized in Table I. Aneurysms
5.5 cm in men or 5.0 cm in women were offered repair as
well as aneurysms twice the diameter of the normal infrare-
nal aorta.
Device selection was based on instructions for use for
each device. All three devices required a proximal neck of
15 mm, and the AneuRx and Excluder required proximal
neck diameter of26mm. The Zenith required a proximal
neck diameter of 32 mm; therefore, all necks 28 mm
were treated with the Zenith. Aneurysms with an infrarenal
neck of26 mm were treated with any of the three devices
according to surgeon discretion and preoperative aneurysm
morphology.
Operative technique. All patients underwent EVAR
with one of three contemporary low-permeability devices as
follows: 47 Zenith, 46 AneuRx with Resilient Graft Mate-
rial, and 29 Excluder with low-porosity PTFE. The new
AneuRx Resilient Graft Material was improved by increas-
ing the twist per inch from 6 to 12 compared with the older
reduced-porosity material. The raw material of the graft
was unchanged. The increased twist per inch results in a
52% greater density of the graft and a 50% reduction in
permeability. The Excluder graft now consists of an ex-
panded PTFE (ePTFE) graft, a low-permeability film layer,
and an ePTFE reinforcing film to reduce graft permeability
compared with the older Excluder device without the
Table I. Demographics of patients
Characteristica Zenith (n  47)
Age, years 74.9
Comorbidities, No. 2.3
AAA size, mm 57.3
Neck diameter, mm 28.6  1.1
Neck length, mm 17.4  0.6
Renal aortic bifurcation length, mm 105.3  15.1
Right CIA diameter, mm 15.4  4.1
Left CIA diameter, mm 15.3  3.9
Renal–right iliac bifurcation, mm 155.3  19.1
Renal–left iliac bifurcation, mm 156.5  18.5
AAA, Abdominal aortic aneurysm; CIA, common iliac artery.
aData are presented as the mean  SD.ePTFE reinforcing film.Angiography was performed to localize the renal arter-
ies with the main device in place. The main body was
deployed under fluoroscopic imaging. Completion angio-
grams were used to assess for graft patency and endoleak,
and intravascular ultrasound (IVUS) was used to assess gate
cannulation during the procedure as well as the stent graft
to vessel wall apposition and length.
Data collection. Patients were followed up prospec-
tively with CTA at 1-, 3-, 6-, and 12-month intervals, and
then biannually. Data for all patients were captured pro-
spectively in a vascular database and retrospectively re-
viewed. Standard axial two-dimensional CT measurements
were obtained and compared with preoperative imaging.
Changes in sac size, aneurysmal morphology, and the pres-
ence of endoleak were compared among the different de-
vices.
The preoperative scan served as a baseline. Preoperative
measurements recorded included neck diameter, neck
length, aneurysm size, renal aortic bifurcation length, com-
mon iliac artery diameter, and distance from the lowest
renal to the iliac bifurcation. The minor axis diameter,
measured at the largest axial cut of the abdominal aortic
aneurysm, was compared with the same measurement at
follow-up. Theminor axis was used to avoid overestimation
of aneurysm size at points of angulation. To avoid interob-
server variability and possible bias, all sac measurements
were obtained retrospectively by a single observer who was
not directly involved in patient care. Diameter changes 5
mmwere considered significant for sac regression or expan-
sion based on the Ad Hoc Committee for Standardized
Reporting practices in Vascular Surgery of The Society for
Vascular Surgery/American Association for Vascular Sur-
gery.8
Statistical analysis. Patient demographics were re-
ported. Changes in aneurysm sac size are presented as
mean  standard deviation and as a percentage increase or
decrease from original size. Analysis of variance was used to
analyze differences between patients implanted with the
three graft types. A value of P  .05 was considered
AneuRx (n  46) Excluder (n  29) P
73.2 73.2 NS
2.4 2.3 NS
56.8 57.1 NS
25.4  0.9 25.2  0.8 .05
17.6  0.8 17.9  0.7 NS
106.6  12.4 103  13.5 NS
15.5  4.6 14.9  3.7 NS
15.6  4.2 15.0  3.6 NS
158.0  17.9 154.5  18.0 NS
157.7  17.0 154.8  16.9 NSstatistically significant.
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Between September 2004 and May 2006, 122 patients
underwent EVAR at two institutions in Texas, during
which 47 Zenith, 46 AneuRx with Resilient Graft Material,
and 29 Excluder with low-porosity PTFE were implanted
in the infrarenal aorta. The mean follow-up was 22.7 3.9
months for all patients, with no significant differences in the
length of follow-up between the groups. There was 100%
follow-up at 1 month for all patients. At 6 months there
were 40 Zenith (85%), 38 AneuRx (83%), and 25 Excluder
(86%) available for follow-up studies; at 12 months there
were 35 Zenith (75%), 33 AneuRx (72%), and 20 Excluder
(69%) available; and at 18 months there were 29 Zenith
(62%), 27 AneuRx (57%), and 17 Excluder (58%) available.
Late deaths not related to the aneurysm occurred in four
patients receiving the Zenith, three receiving the AneuRx,
and two receiving the Excluder.
Patient demographics, including age, sex, comorbidi-
ties, preoperative aneurysm morphology, and mean maxi-
mum aneurysm diameter at baseline, were similar among
the three groups (Table I). Technical success was 100%,
with no intraoperative conversions. No deaths occurred
30 days. No stent fractures, late surgical conversions, or
aneurysm ruptures occurred during follow-up. There have
been two graft migrations with the Zenith requiring place-
ment of proximal cuffs for type I endoleaks, one migration
not requiring intervention and one limb thrombosis requir-
ing femorofemoral bypass with the AneuRx, and one mi-
gration of an Excluder did not require intervention.
The overall rate of endoleak was not significantly dif-
ferent; specifically, the rate of type II endoleak at 6 months
was Zenith, 17%; AneuRx, 17%; and Excluder, 14%. Dur-
ing this period of implantation with the contemporary graft
materials, no secondary interventions were performed for
type II endoleaks. The senior authors (C. J. B., and
F. R. A.) treat type II endoleaks conservatively, requiring a
5-mm increase in aneurysm size from the first postoper-
ative CTA before treatment.
Device-specific sac morphology is given in Table II. At
1 year, sac size decreased by 10.4  2.6 mm with the
AneuRx, 6.7 1.9mmwith the Zenith, and 3.4 0.9mm
with the Excluder (P .05). Sac regression was maintained
out to 18 months with the three devices as well, with
Dacron stent grafts having significantly greater sac regres-
Table II. Aneurysm diameter changes after endovascular
aneurysm repair
Time
(months)
Zenith
(n  47)
AneuRx
(n  46)
Excluder
(n  29)
P% Decrease % Decrease % Decrease
1 3.9 8.9 1.2 .05
6 2.4 11.4 1.0 .05
12 11.9 18.4 5.7 .05
18 11.0 18.9 5.5 .05sion than the Excluder graft. At 18 months, sac size de-creased by 12.7 2.7 mmwith the AneuRx, 6.4 1.8 mm
with the Zenith, and 3.3 0.9 mmwith the Excluder (P
.05). The percentage of sac regression during our follow-up
is shown in Fig 1, and absolute sac regression is demon-
strated in Fig 2. At 1 year, 65% of patients with the AneuRx,
63% with the Zenith, and 34% with Excluder stent grafts had
aneurysm sac shrinkage of 5 mm. The aneurysm in one
patient with a type II end leak and an AneuRx stent graft
increased from 57 to 63 mm during a 3-year span, but no
treatment was initiated because he was recently diagnosed
with metastatic cancer. Among all graft types, 19 patients
(8.06%)with a type II endoleak experienced a smaller decrease
in sac size compared with the 84 patients (15.43%) without
endoleak at the 6-month follow-up (Fig 3).
DISCUSSION
Since its advent, EVAR has become widely accepted for
the treatment of patients with abdominal aortic aneurysms;
however, long-term imaging surveillance is indicated sec-
ondary to concerns of long-term durability. Imaging is
intended to identify endograft failures resulting from stent
fractures, graft migration, and persistent endoleak that lead
to sac enlargement. Sac enlargement after EVAR is indica-
Device Specific Percent Sac 
Regression
0.00%
5.00%
10.00%
15.00%
20.00%
Zenith AneuRx Excluder
Device Type
Pe
rc
en
t S
hr
in
ka
ge
1 month
6 month
12 month
18 month
Fig 1. Device-specific percentage of sac regression.
Absolute Sac Regression Over Time
0
2
4
6
8
10
12
14
Zenith AneuRx Excluder
Device Type
Sa
c 
R
eg
re
ss
io
n 
(m
m
)
1 month
6 month
12 month
18 month
Fig 2. Device-specific sac regression.tive of continued sac pressurization with failure to fully
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concerning for continued risk of rupture.
Multiple trials have now lent support to indicate that
rates of sac expansion or regression after EVAR are strongly
correlated with the graft type implanted.1-6 The original
Excluder device has the highest reported rates of sac en-
largement, demonstrated to occur in up to 37% of patients
at 4 years.8 Upon review of surveillance CT scans of those
patients in the original Gore Excluder Pivotal Trial, Fill-
inger13 demonstrated that up to 74% of enlarging sacs after
EVAR could be attributable to endotension, which is the
continued pressurization of the sac with subsequent sac
enlargement in the absence of apparent endoleak. It is
generally thought that the development of endotension
with this graft has been attributable to the permeability of
the graft fabric allowing serous transudate to pass through
the material contributing to continued sac pressurization.
Aneurysms treated with early generation AneuRx grafts
often had a stable sac size after repair, without evidence of
regression or expansion; however, these have been associ-
ated with a higher incidence of microleaks, or persistent
transgraft blood flow, occurring through the thin graft
material. Although these type IV endoleaks often sponta-
neously thrombose and do not usually require secondary
intervention,7,11,12 they are likely the cause of the reported
lower rates of sac regression seen with this graft.
The Zenith stent graft, designed with a low-permeability
Dacron fabric, has been associatedwith the highest rates of sac
regression and has often served as a basis of comparison for
trials reviewing sac size change after EVAR with the Gore
Excluder and Medtronic AneuRx grafts. Trials have esti-
mated that up to 77% of aneurysms treated with the Zenith
endografts experience sac regression and only 0.6% experi-
ence sac enlargement.14 Trials comparing these three grafts
before 2004, before Gore and Medtronic updated their
graft material, consistently demonstrated lower rates of sac
enlargement with the Zenith endografts. Sternbergh et al2
demonstrated a sac regression of 7.6 mm with the Zenith
and 3.5 mm with the AneuRx at 12 months. Greenberg et
al3 demonstrated less regression with the original Excluder
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Fig 3. Effect of endoleak on sac regression at 6-months.compared with the Zenith. They further demonstratedthat even in the presence of a small endoleak, the aneu-
rysms treated with Zenith endografts would continue to
decrease in volume whereas the sac size of those treated
with the Excluder would increase. Ouriel et al7 further
demonstrated that sac shrinkage was most common with
the Zenith endograft compared with pre-2004 Talent,
AneuRx, and Excluder devices.7
Since the aforementioned studies were conducted, how-
ever, bothGore andMedtronic have released updated devices
with material adjustments to the Excluder and AneuRx, re-
spectively. In 2004, Gore released an updated version of the
Excluder endograft that now has a low-permeability layer in
attempt to reduce flow across the PTFE graft fabric. Haider
et al1 have since reported that sac shrinkage rates after EVAR
with the Gore Excluder low-permeability device are signifi-
cantly higher than the rates with the original Gore Excluder
(63.9% vs 25%, P .001) and similar rates comparedwith the
Zenith endograft (65.3%). Goodney et al10 further demon-
strated that aneurysms treated with the original Excluder
could be relined with the low-permeability updated Gore
Excluder, with resultant stabilization and even sac regres-
sion in several patients. Also in 2004, Medtronic updated
the graft material used in the AneuRx graft to the Resilient
Graft Material made of reduced-porosity Dacron. Rates of
sac regression since the changes in this material have not
been directly examined.
Our results at 12 months demonstrated a significant sac
size reduction for theAneuRx andZenithDacron stent grafts,
defined as 5 mm by The Society of Vascular Surgery.8
Aneurysms treated with the updated AneuRx device experi-
enced a sac regression significantly greater than the Zenith
stent graft, a finding contrasting with prior studies with earlier
AneuRx graft materials. Although our data show a lower rate
of sac regression with the Zenith endograft compared with
rates reported in the literature, this maybe attributed to our
tendency to use this graft inmore complex aneurysm anatomy
with larger neck diameters. Intuitively, in the absence of
significant endoleaks and with successful aneurysm exclusion,
sac regression should be equivalent. However, intermittent or
undiagnosed problems with proximal and distal seal may lead
to repressurization of the sac and a decrease in the percentage
of aneurysms that experience regression when treated with
this graft.
Although the Gore Excluder did not meet the 5-mm
requirement for regression at 12 months, a trend toward
decreasing sac size was observed. Recent series have demon-
strated equivalent rates of sac shrinkage seen after use of the
new Excluder and the Zenith endografts.3 The Excluder,
however, demonstrated a significantly lower absolute sac re-
gression compared with the AneuRx and Zenith grafts at the
1-, 6-, and 12-month time intervals in our series. Further-
more, although all contemporary grafts appear to successfully
exclude the aneurysm and prevent sac enlargement during a
12-month follow-up, those grafts designed with thicker Da-
cron graftmaterial experienced significantly greater sac regres-
sion than those designed with thin-walled PTFE.
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cidence of endoleaks has been reported. Ouriel et al,7 has
suggested an increased rate of type II endoleaks with the
Excluder (original material) possibly accounting for in-
creased incidence of sac growth. Sheenan et al,15 however,
demonstrated only slight variation in the early incidence of
type II endoleak but concluded that the long-term preva-
lence is difficult to assess secondary to events over time,
including spontaneous resolution of endoleaks, develop-
ment of new endoleaks, and initial aneurysm size. Although
the rate of type II endoleak among the varying graft types in
our series was similar, we noted that the rate of sac regres-
sion was smaller in those with endoleak compared with
those without. This finding is consistent with prior investi-
gations and certainly not unexpected as the mechanism of
endoleak leads to intermittent or continuous sac pressur-
ization, albeit often less than full systemic pressure.
One potential weakness of our trial lies in the short-
term follow-up. Several trials have shown early sac regres-
sion followed by reexpansion after 12 to 36 months in the
original Excluder device.9,16 Furthermore, aortic calcifica-
tion has been implicated as a causative factor in the failure of
aneurysm sac regression after EVAR. Postulated mecha-
nisms suggest a decrease in wall compliance and a resultant
increase in endotension.4 Rhee et al17 suggest that aortic
calcification should be considered a mitigating factor in
failed sac regression when there is 75% to 100% circumfer-
ential involvement of the aorta. A second limitation of this
study, therefore, is that we did not compare the degree of
aortic calcification between the grafts, thereby leaving a bias
against any graft used in aortas with heavier calcification. It
is unlikely, however, that the difference among the groups
would be statistically significant.
CONCLUSION
Although device-specific results and sac regression have
been studied in the past, to our knowledge this is the first
study to date to evaluate device specific sac regression with
both the contemporary Excluder and AneuRx devices. The
introduction of newgeneration graftmaterials appears to have
favorably influenced sac regression with all devices. These are
improved compared with published reports of older genera-
tion graft materials of the AneuRx and Excluder. However,
there is a trend toward greater sac regression with devices
made with Dacron compared with PTFE. The relationship of
aneurysm morphology and long-term effects on aortic stent
grafts is yet to bedetermined. Itwill be important to follow-up
these patients to determine durability.
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Dr Todd Rassmussen (San Antonio, Tex). I thank you for
the opportunity to review this and comment on the paper. I
commend the authors for affording me the manuscript in advance
and I enjoyed reading it and I congratulate the group from UT
Southwestern on yet another clear, concise, neat, and germane
manuscript. It was a good read and a nice presentation.
Because of the late hour, I won’t summarize the whole manu-
script. I do, however, have a couple of specific questions andmaybe
you can clarify for me and the group. One pertains to the baseline
similarity or dissimilarity potentially between the aneurysms com-
pared in each of the three groups. As your group knows and has
recently published, the characteristics of the aortic neck are very
important in EVAR and yet in the manuscript there are no data on
the neck anatomy between the three groups. No comparisons.
There are no lengths. No diameters. No calcification scores. There
is really no characterization of the necks in the three groups. And in
the absence of this information, can the authors really be sure of
that valid comparisons can be made between the three groups or
among the three groups? In other words, were regression rates so
favorable in the Medtronic group because the AneuRx grafts were
placed in aneurysms with longer, less dilated necks, easier aneu-
rysms, so to speak? Was there an incidence of graft migration at 1
year? Was there any incidence of Type I endoleaks in any of the
groups?
The second and third questions really just pertain to clinical
relevance and maybe put you on the spot with regards to your
findings. Help us relate this to our practices. First of all, assuming
these trends hold true in longer follow-up, what is their clinical
relevance, would they impact your selection of grafts in the future?
In other words, would you not use a specific graft because its rate
of regression was 5% or 10% less than another graft at 1 year? Is it
clinically relevant or are we just gilding the lily here?
And then lastly relates to the follow-up, which youmentioned,
can we really make after EVAR—given what several groups around
the country observed the expansion at 2 or 3 years—can we reallymake valid comparisons with only a 12-month follow-up? Again, I
commend you on you paper. I think it has a lot of potential and you
did a nice presentation.
Dr Harshal Broker. Thank you for those questions. To
address your first question about the neck anatomy. We found that
there were no differences between the aortic neck except that the
Zenith graft was used in patients with larger necks, since this is the
only graft currently available to treat necks greater than 28 mm;
otherwise, there were no differences between the three groups.
Again it should be noted that even with those who received the
Zenith graft, there were no type I endoleaks and no evidence of
type I endoleaks at 1 year. Furthermore, we found no differences
between the groups with regard to type II endoleaks. So as far as we
can tell, the aneurysm morphology between the three groups was
fairly similar. The overall importance of sac shrinkage is unknown
and how much is enough is uncertain. However, as an implanting
physician, it is comfortable to know that the aneurysm is shrinking
and it also comforts the patient as well. Certainly, it is important to
follow these patients to see if these trends persist.
Unidentified speaker. I have two quick questions. There are
pretty good data showing that volumetric analysis is more sensitive
than actual size. Did you look at any volumetric data? And the
second question, we have reported out of our core lab data that
there is an endoleak influence on the rate of sac either expansion or
regression amongst devices. Did you notice any difference when
you looked at the influence of endoleak on sac regression or
expansion in your study?
Dr Broker. As far as volumetric data, we did not look at that,
but I think we do have the data to go back and look in this definite
option to maybe strengthen the paper. In patients with type II
endoleaks, there was still sac regression but it was significantly less
than in those patients who did not have any endoleak. Because of
the overall small number of patients with type II endoleak, we did
not look at device specific outcomes in this regard.
